Semaglutide CAS NO.99291-20-0

WLP Ingredient Inc was formerly known as Green Valley Biochemical, which was founded in Hong Kong in 2013 and WLPI was officially registered in 2019. In 2023, it reached a long-term strategic cooperation agreement with a local factory of plant extract. which already got HAHAL,KOSHER,ISO9001,ISO2200,HACCP,cGMP

Now it has developed into a comprehensive enterprise integrating R&D, production and sales. And after years of market accumulation and in response to customer needs, we have close cooperation in various fields and production such as human APIs, veterinary APIs, food additives, feed additives, vitamins, amino acids, etc

In the course of business, our company has always adhered to the principle of integrity first and won the praise of our customers. we hope that in the days to come,we can become your important partner and create a better future together

Semaglutide, with the CAS registry number 910463-68-2, a once-weekly glucagon-like peptide-1 receptor agonist, has shown promise in weight management and cardiovascular outcomes. Semaglutide can reduce the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. Among heart failure with preserved ejection fraction (HFpEF) patients and type 2 diabetes, semaglutide led to larger reductions in heart failure–related symptoms and physical limitations and greater weight loss than placebo at 1 year. Semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight, and N-terminal pro-brain natriuretic peptide, regardless of baseline health status. The benefits of semaglutide extended to all key KCCQ(Kansas City Cardiomyopathy Questionnaire) domains. In overweight or obese non-diabetic individuals, semaglutide had a remarkable and sustained weight loss effect that was well tolerated and safe.